SCH-39304 in Prevention and Treatment of Disseminated Candidiasis in Persistently Granulocytopenic Rabbits

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 1990 Aug 1

PMID 2221866

Citations 6

Authors

T J Walsh

J W Lee

J Lecciones

P Kelly

J Peter

V Thomas

J Bacher

P A Pizzo

Affiliations

Soon will be listed here.

Abstract

To investigate the potential use of SCH-39304 for the prevention and treatment of disseminated candidiasis in granulocytopenic patients, we studied its in vivo antifungal activity as preventive, early, and late treatments in three models (acute, subacute, and chronic) of disseminated candidiasis in persistently granulocytopenic rabbits. SCH-39304 was an effective as amphotericin B alone and fluconazole alone for the prevention of disseminated candidiasis. SCH-39304 alone and fluconazole alone were as effective as amphotericin B plus flucytosine for early treatment of subacute disseminated candidiasis. When treatment was delayed for 5 days to establish chronic disseminated candidiasis, SCH-39304 was less effective than amphotericin B plus flucytosine. In comparison with different treatment regimens, SCH-39304 was more effective in early and preventive treatment. Thus, SCH-39304 was comparable to treatment control regimens in prevention and early treatment of subacute disseminated candidiasis. SCH-39304 also was most effective in granulocytopenic rabbits with disseminated candidiasis when used for prevention or early treatment.

Citing Articles

Hydroxysulfonylation of alkenes: an update.

Hossaini Z, Mahmood E, Poor Heravi M, Ebadi A, Vessally E RSC Adv. 2022; 11(35):21651-21665.

PMID: 35478812 PMC: 9034158. DOI: 10.1039/d1ra00513h.

Pharmacokinetics of the triazole antifungal agent genaconazole in healthy men after oral and intravenous administration.

Mojaverian P, Radwanski E, Affrime M, CAYEN M, Lin C Antimicrob Agents Chemother. 1994; 38(12):2758-62.

PMID: 7695258 PMC: 188281. DOI: 10.1128/AAC.38.12.2758.

Effects of antifungal therapy on inflammation, sterilization, and histology in experimental Candida albicans meningitis.

Jafari H, Saez-Llorens X, Severien C, Parras F, Friedland I, Rinderknecht S Antimicrob Agents Chemother. 1994; 38(1):83-9.

PMID: 7511361 PMC: 284401. DOI: 10.1128/AAC.38.1.83.

In vitro and in vivo activities of SCH 42427, the active enantiomer of the antifungal agent SCH 39304.

Loebenberg D, Cacciapuoti A, PARMEGIANI R, Moss Jr E, Menzel Jr F, Antonacci B Antimicrob Agents Chemother. 1992; 36(2):498-501.

PMID: 1605621 PMC: 188469. DOI: 10.1128/AAC.36.2.498.

Comparison of SCH 39304, fluconazole, and ketoconazole for treatment of systemic infections in mice.

Cacciapuoti A, Loebenberg D, PARMEGIANI R, Antonacci B, Norris C, Moss Jr E Antimicrob Agents Chemother. 1992; 36(1):64-7.

PMID: 1590702 PMC: 189227. DOI: 10.1128/AAC.36.1.64.

References

Savani D, Perfect J, Cobo L, Durack D . Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob Agents Chemother. 1987; 31(1):6-10. PMC: 174641. DOI: 10.1128/AAC.31.1.6. View

Walsh T, McEntee C, DIXON D . Tissue homogenization with sterile reinforced polyethylene bags for quantitative culture of Candida albicans. J Clin Microbiol. 1987; 25(5):931-2. PMC: 266122. DOI: 10.1128/jcm.25.5.931-932.1987. View

Thaler M, Pastakia B, Shawker T, OLeary T, Pizzo P . Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med. 1988; 108(1):88-100. DOI: 10.7326/0003-4819-108-1-88. View

Saag M, Dismukes W . Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother. 1988; 32(1):1-8. PMC: 172087. DOI: 10.1128/AAC.32.1.1. View

Thaler M, Bacher J, OLeary T, Pizzo P . Evaluation of single-drug and combination antifungal therapy in an experimental model of candidiasis in rabbits with prolonged neutropenia. J Infect Dis. 1988; 158(1):80-8. DOI: 10.1093/infdis/158.1.80. View

Walsh T, Lee J, Aoki S, Mechinaud F, Bacher J, Lecciones J . Experimental basis for use of fluconazole for preventive or early treatment of disseminated candidiasis in granulocytopenic hosts. Rev Infect Dis. 1990; 12 Suppl 3:S307-17. DOI: 10.1093/clinids/12.supplement_3.s307. View

Graybill J . Systemic fungal infections: diagnosis and treatment. I. Therapeutic agents. Infect Dis Clin North Am. 1988; 2(4):805-25. View

McIntyre K, Galgiani J . In vitro susceptibilities of yeasts to a new antifungal triazole, SCH 39304: effects of test conditions and relation to in vivo efficacy. Antimicrob Agents Chemother. 1989; 33(7):1095-100. PMC: 176068. DOI: 10.1128/AAC.33.7.1095. View

Perfect J, Wright K, Hobbs M, Durack D . Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304. Antimicrob Agents Chemother. 1989; 33(10):1735-40. PMC: 172747. DOI: 10.1128/AAC.33.10.1735. View

10.

Lee J, Lin C, Loebenberg D, Rubin M, Pizzo P, Walsh T . Pharmacokinetics and tissue penetration of Sch 39304 in granulocytopenic and nongranulocytopenic rabbits. Antimicrob Agents Chemother. 1989; 33(11):1932-5. PMC: 172790. DOI: 10.1128/AAC.33.11.1932. View

11.

Walsh T, Aoki S, Mechinaud F, Bacher J, Lee J, Rubin M . Effects of preventive, early, and late antifungal chemotherapy with fluconazole in different granulocytopenic models of experimental disseminated candidiasis. J Infect Dis. 1990; 161(4):755-60. DOI: 10.1093/infdis/161.4.755. View

12.

Walsh T, Bacher J, Pizzo P . Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits. Lab Anim Sci. 1988; 38(4):467-71. View